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ABSTRACT SUMMARY: 
     Self-nanoemulsifying drug delivery systems 
(SNEDDs) prepared from GRAS excipients (Labrafil 
M1944CS: Labrasol: Capryol 90: BPQ 30: 59 : 10 : 
1% w/w/w/w) enhance the oral bioavailability of a 
poorly soluble antiparasitic drug, Buparvaquone 
(BPQ), while maintaining in vitro efficacy against L. 
infantum promastigotes. BPQ-SNEDDs possess high 
loading and excellent stability to tropical 
temperatures while allowing for the complete 
dissolution of BPQ in simulated gastrointestinal 
media. We hypothesise that the enhanced 
solubilisation capacity of BPQ in the GI tract is 
responsible for the enhanced oral bioavailability. 
Adsorption of prepared BPQ-SNEDDs on solid 
carriers (glycol chitosan) and lyophilisation resulted 
in a solid nanomedicine that can be reconstituted to 
yield stable BPQ-SNEDDs of nanomolar in vitro 
activity.   
 
INTRODUCTION: 
     Visceral Leishmaniasis (VL) is the second 
deadliest parasitic disease after malaria 
1
. Since 
there are no effective vaccines to prevent 
Leishmania infections, management of VL relies on 
parenteral antimonials (first-line), pentamidine, 
paromomycin, and amphotericin B or its lipid 
formulations. Miltefosine is the only oral therapy but, 
the risk of resistance is very high which reduces its 
clinical usefulness 
1
.  Treatment of parasitic diseases 
are hampered by the lack of an oral technology 
platform able to deliver antiparasitic poorly soluble 
drugs in adequate amounts to the tissues of interest 
(liver and spleen), along with increased cost, low 
safety margin and thermal instability of available 
effective therapies. Buparvaquone (BPQ), an 
antiprotozoal hydroxylnaphtoquinone with known 
anti-Leishmaniasis activity in vitro (ED50: 0.05-
0.1μM), has not been translated into an effective 
therapy due to its low aqueous solubility (< 30 ng 
mL
-1
, BCS Class II drug) 
1,2
. The current project is 
aimed at enhancing the solubilisation capacity of 
BPQ in the gut and its oral bioavailability by 
encapsulation in a lipid based self-nanoemulsifying 
drug delivery systems (SNEDDs) and develop an oral 
thermally stable and ideally solid nanomedicine for 
the treatment of VL.  
 
EXPERIMENTAL METHODS: 
      Pseudo-ternary phase diagrams were constru-
cted to identify the microemulsion regions and to 
optimize the concentrations of oil (Oleoyl macrogol-6 
glycerides, Labrafil M1944CS), surfactant (Caprylo-
caproyl macrogol-8 glycerides, Labrasol), and 
cosurfactant (Propylene glycol monocaprylate, 
Capryol 90) 
2
. BPQ was solubilised in Labrasol and 
the oil and co-surfactant were added. BPQ SNEDDs 
were left stirring (50 rpm) over 24h in a waterbath at 
37
o
C. BPQ loading was quantified after 
centrifugation of prepared SNEDDs containing 10, 
20, 50 mg g
-1
 of SNEDDs (14,000 rpm for 15 
minutes) using a modified RP - HPLC method 
[Phenomenex Onyx Monolithic C18 column (5µm, 
4.6 mm x 10+100+100 mm), flow rate 1.5 mL min
-1
, 
injection volume: 40 µL] 
2
.BPQ SNEDDs were 
characterised for particle size (PCS), zeta potential 
and morphology (TEM). The dissolution of BPQ from 
BPQ-SNEDDs loaded capsules (NP Caps
TM
, pullu-
lan, Capsugel) was studied in the flow through cell 
(USP, Apparatus IV) at various pH levels [USP 2013 
simulated gastric fluid without pepsin (1.2), acetate 
buffer (4.5) and phosphate buffer (6.8), flow rate 6ml 
min
-1
] 
3
. Stability studies of BPQ SNEDDs were 
performed at 40± 2
o
C and 75±5% relative humidity 
(RH) over 3 months. BPQ - solid SNEDDs were 
prepared by adsorption of BPQ - SNEDDs (2mls, 
BPQ 1% w/w) on glycol chitosan (200kDa, 0.4g) and 
mixed in a mortal with lactose (3.1g) prior to the 
addition of 60mls of water and lyophilisation. Solid 
SNEDDs were characterised using PXRD and DSC. 
The in vitro anti-leishmanial activity against L. 
infantum promastigotes was performed for both 
BPQ-SNEDDs and BPQ - solid SNEDDs 
4
.  RP-
HPLC was used to analyse acetonitrile extracted 
plasma samples obtained after oral administration of 
BPQ SNEDDs and BPQ aqueous suspension 
prepared by probe sonication (50% output, 200 watt 
for 10 minutes).  
      
RESULTS AND DISCUSSION: 
     Phase diagrams illustrated that the optimal 
microemulsion region can be achieved using an oil to 
a constant surfactant: co-surfactant ratio of 1:6.8 w/w 
or above. BPQ SNEDDs (Labrafil M1944CS: Labra-
sol: Capryol 90: BPQ 30: 59 : 10 : 1% w/w/w/w). 
BPQ-SNEDDs and reconstituted BPQ - solid 
SNEDDs were quasispherical and below 400nm and 
(228 ± 1nm and 279 ± 52 nm, polydispersity index: 
0.121 ± 0.017 and 0.365 ±0.042, zeta potential: -22 ± 
4.4mV and -8.94 ± 4.2 mV respectively) (Figure 1A, 
B) 
5
. The maximum loading of BPQ was identified to 
be 16.92 ± 1.59 mg g
-1
 in BPQ- SNEDDs and 5.71 ± 
0.54 mg g
-1
 for BPQ - solid SNEDDs. Near complete 
release (89.3±1.9%) was observed in flow-through 
cell studies with BPQ-SNEDDs filled capsules within 
30 minutes (pH1.2) (Figure 1C). Drug loading and 
particle size of BPQ-SNEDDs remained unaltered 
over 3 months (40 ± 2
o
C, 75±5% RH, p<0.05).  
 
 
 
         
Figure 1: A,B; Transmission electron microscopy 
images of BPQ-SNEDDs (1:200 dilution) and 
reconstituted BPQ - Solid SNEDDs (1µg mL
-1
 in 
water – 200kDa glycol chitosan) (Bar: 500 nm), C; % 
Cumulative BPQ release from BPQ-SNEDDs (pH 
1.2: 0-30min, pH 4.5: 30-60 min, pH 6.8: 60-80 min), 
D; DSC curves at 10
o
C min
-1 
of BPQ - solid SNEDDs 
and E; PXRD analysis of BPQ - solid SNEDDs 
 
   BPQ and lyophilized BPQ are crystalline materials 
characterized by a strong endothermic peak at 
183°C corresponding to the melting point of the drug 
(Figure 1D). BPQ-SNEDDS exhibit an endothermic 
peak at the same onset temperature that the 
unmodified drug but also glass transition and 
crystallization peaks which indicate that the drug is at 
least partially amorphised. BPQ exhibits Bragg 
peaks characteristic of crystalline material even after 
lyophilisation (Figure 1E). BPQ – solid SNEDDs 
resulted in fewer Bragg peaks which were broader 
and of lower intensity. The absence of the 
characteristic peaks of BPQ (2θ
o
: 6.55) indicates the 
amorphisation of BPQ.   
   BPQ – SNEDDS and BPQ – solid SNEDDs 
showed potent in vitro efficacy in the nanomolar 
range against L infantum similar to BPQ in DMSO 
(IC50 for all <37nM) while having negligible 
cytotoxicity. BPQ-SNEDDs significantly enhance the 
bioavailability of BPQ compared to aqueous 
dispersions of BPQ after oral administration (55% 
increase in plasma AUC 0-24).* 
 
Figure 2: Buparvaquone plasma concentration after 
oral administration of BPQ (aqueous suspension – 
probe sonicated, rhombus) and BPQ-SNEDDs (1.1% 
w/w, square) formulations to CD-1 mice (n=3, 
Student t-test: *p<0.05, dose: 6 mg kg
-1
 of BPQ).  
 
CONCLUSION: 
    The present study demonstrates for the first time 
enhancement of the oral bioavailbility of a poorly 
soluble antiparasitic drug, buparvaquone, in mice 
with SNEDDs. BPQ-SNEDDs illustrated high 
loading, particle size below 400nm, quasispherical 
morphology, excellent stability at tropical conditions 
and in vitro efficacy in the nanomolar range. 
Reconstitution of prepared BPQ - solid SNEDDs by 
adsorption of BPQ-SNEDDs on glycol chitosan and 
lyophilisation resulted in a liquid nanoemulsion with 
comparable in vitro efficacy. Studies on the 
dissolution properties and the oral bioavailbility and 
efficacy of BPQ- solid SNEDDs are underway. 
Developed SNEDDs or solid-SNEDDs prepared from 
GRAS excipients are cost-effective, stable oral 
alternatives for the delivery of poorly soluble 
antiparasitic drugs. 
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